InSite Vision says phase 3 studies show effectiveness of AzaSite in treatment of bacterial conjunctivitis

By Lisa Kerner

Charlotte, N.C., Aug. 3 - InSite Vision Inc. said results from two phase 3 studies show the effectiveness of AzaSite in the treatment of bacterial conjunctivitis and bacteria eradication.

In the first study, AzaSite, dosed twice daily for the first two days and once daily for three more days, was equivalent to tobramycin dosed four times daily for five days in resolving clinical signs and symptoms of bacterial conjunctivitis.

The second phase 3 study was a double-blinded, vehicle-controlled trial that demonstrated the effectiveness of AzaSite in clinical resolution of the signs and symptoms of bacterial conjunctivitis and bacterial eradication.

InSite said both trials revealed a superior safety profile of AzaSite.

"These clinical trial results support AzaSite's value proposition of established efficacy and coverage with the convenience and compliance of a once-a-day dosing regimen," chief executive officer Kumar Chandrasekaran said in a company news release.

The efficacy and safety data will be presented at the American Academy of Ophthalmology in Las Vegas in November.

InSite Vision is an Alameda, Calif., ophthalmic company developing therapies to treat ocular infections, glaucoma and retinal diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.